Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 1,200,775 thousand, a decrease of 3.5% from RMB 1,244,458 thousand in 2023[2] - Gross profit for the same period was RMB 365,911 thousand, down 8.1% from RMB 398,236 thousand, resulting in a gross margin of 30.5% compared to 32.0% in 2023[3] - The net loss for the year was RMB 269,158 thousand, an improvement of 14.3% from a net loss of RMB 313,882 thousand in 2023[5] - Adjusted net profit (non-IFRS) was RMB 22,764 thousand, down 42.5% from RMB 39,411 thousand in the previous year[2] - The company reported a total comprehensive loss of RMB 268,137 thousand for the year, compared to RMB 312,655 thousand in 2023, indicating a reduction in overall losses[5] - The group reported a pre-tax loss of RMB 263,799 thousand for 2024, compared to a loss of RMB 320,945 thousand in 2023, showing an improvement of approximately 17.8%[21] - Basic loss per share for 2024 was RMB 0.375, based on a weighted average of 715,492,000 shares, compared to RMB 0.465 for 2023 with 667,095,000 shares[27] - Net loss decreased by 14.2% from RMB 313.9 million in 2023 to RMB 269.2 million in 2024[56] Revenue Breakdown - Revenue from enterprise services and digital marketing services amounted to RMB 950,866 thousand in 2024, compared to RMB 945,798 thousand in 2023, indicating a growth of about 0.2%[20] - The healthcare services segment generated revenue of RMB 249,669 thousand in 2024, down from RMB 297,452 thousand in 2023, reflecting a decrease of approximately 16.1%[20] - Revenue from healthcare services decreased from RMB 297.5 million in 2023 to RMB 249.7 million in 2024, a decline of 16.1%[45] - Revenue from enterprise services and digital marketing services increased from RMB 945.8 million in 2023 to RMB 950.9 million in 2024, a growth of 0.1%[45] - The revenue from health membership plans was RMB 120.979 million in 2024, consistent with 10.1% of total revenue, unchanged from 2023[44] Expenses and Costs - Research and development expenses increased to RMB 103,400 thousand from RMB 96,981 thousand, reflecting a focus on innovation[3] - The total sales cost decreased by 1.3% from RMB 846.2 million in 2023 to RMB 834.9 million in 2024[46] - Selling expenses decreased by 4.1% from RMB 211.8 million in 2023 to RMB 203.2 million in 2024, due to reduced marketing expenses for healthcare service packages[49] - Administrative expenses decreased by 32.3% from RMB 79.8 million in 2023 to RMB 54.0 million in 2024, primarily due to reduced office expenses[50] - R&D costs decreased by 6.2% from RMB 103.4 million in 2023 to RMB 97.0 million in 2024, as several products were completed in the second half of 2024[51] - Financing costs increased by 36.4% from RMB 3.3 million in 2023 to RMB 4.5 million in 2024, due to increased bank loans to support business expansion[52] Assets and Liabilities - Cash and cash equivalents rose to RMB 260,229 thousand from RMB 168,693 thousand, indicating improved liquidity[6] - Total assets increased to RMB 454,781 thousand in 2024 from RMB 338,950 thousand in 2023, showing growth in the company's asset base[6] - Total liabilities increased to RMB 208,562,000 in 2024 from RMB 193,885,000 in 2023, indicating a rise of approximately 7.6%[31] - The company's current loans and borrowings decreased to RMB 55.5 million as of December 31, 2024, down from RMB 88.5 million in 2023, due to partial repayment of outstanding loans[68] - The total amount of bank loans and borrowings as of December 31, 2024, was RMB 56.4 million, down from RMB 89.0 million in 2023, with interest rates ranging from 3.4% to 14.65%[76] - The company's total net liabilities reversed from RMB 1,652.1 million as of December 31, 2023, to a net asset value of RMB 231.8 million as of December 31, 2024[71] Market and Growth Strategy - The company plans to continue expanding its digital marketing and healthcare services, aiming for market growth in these sectors[8] - The group has three main segments: enterprise services and digital marketing services, healthcare services, and others, with the majority of revenue derived from mainland China[18] - The company expects to improve financial performance and profitability through continuous revenue growth and enhanced cost efficiency, particularly by transforming its pharmaceutical sales, content services, and IT services[77] - The company anticipates expanding collaborations with more physicians to enhance access to real-world clinical data, covering a broader range of diseases and medical conditions[78] Corporate Governance - The company is committed to high standards of corporate governance to protect shareholder interests[84] - The board consists of two executive directors, two non-executive directors, and three independent non-executive directors, ensuring a significant level of independence[83] - The audit committee has reviewed the audited consolidated financial statements for the year ending December 31, 2024, and found no significant changes in accounting policies[88] - The independent auditor has agreed on the consolidated performance data for the year ending December 31, 2024, but did not provide any audit conclusions[89] - The company will continue to review the separation of the roles of chairman and CEO as appropriate[84] Shareholder Information - The company did not declare any dividends for the year ended December 31, 2024[33] - The company issued 25,000,000 shares at a price of HKD 7.80 per share during its IPO, raising approximately RMB 180,471,000 in total[34] - The company's shares were listed on the Hong Kong Stock Exchange on December 30, 2024, marking a significant milestone for its capital market presence[8] - The board does not recommend the distribution of a final dividend for the year ending December 31, 2024[90] - The annual performance announcement will be published on the stock exchange and the company's website[92]
健康之路(02587) - 2024 - 年度业绩